These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Anthony L; Vinik AI Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761 [TBL] [Abstract][Full Text] [Related]
5. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219 [TBL] [Abstract][Full Text] [Related]
6. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786 [TBL] [Abstract][Full Text] [Related]
7. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. Khuroo MS; Khuroo MS; Khuroo NS J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222 [TBL] [Abstract][Full Text] [Related]
9. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. Buscombe JR; Caplin ME; Hilson AJ J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome. Penning C; Vecht J; Masclee AA Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971 [TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report. Saif MW JOP; 2011 Jul; 12(4):425-8. PubMed ID: 21737909 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251 [TBL] [Abstract][Full Text] [Related]
14. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide]. Laczi F; Magony S; Julesz J Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861 [TBL] [Abstract][Full Text] [Related]
15. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Pasieka JL; McEwan AJ; Rorstad O Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579 [TBL] [Abstract][Full Text] [Related]
16. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798 [TBL] [Abstract][Full Text] [Related]